1,5-diphenyl-3-pyridinylamino-1,5-dihydropyrrolidin-2-one as CB1 receptor modulator
申请人:Eli Lilly and Company
公开号:US07998985B2
公开(公告)日:2011-08-16
Compound and pharmaceutical compositions comprising the compounds of the Formula
or a pharmaceutically acceptable salt thereof, as a CB1 receptor inverse agonist, useful for reducing body weight in mammals, treating cognitive impairment associated with schizophrenia, and mitigating treatment emergent weight gain observed during treatment with antipsychotics.
化合物及其药物组合物包括Formula中的化合物或其药学上可接受的盐,作为CB1受体的反向激动剂,对于减轻哺乳动物的体重、治疗与精神分裂症相关的认知障碍以及减轻使用抗精神病药物治疗期间观察到的治疗后体重增加具有用处。